Compare Petróleo Brasileiro SA (PBR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Travere Therapeutics Inc. Common Stock — how do they compare? Petróleo Brasileiro SA trades at $25.95 (market cap $157.24B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Petróleo Brasileiro SA is far larger — about 32.2× Travere Therapeutics Inc. Common Stock's market cap, and Petróleo Brasileiro SA pays a 6.57% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 26 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PBR | TVTX | |
|---|---|---|
Market Cap | $157.24B | $4.88B |
Volume | 17,564,454 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $25.94 | $67.52 |
52-Week Low | $11.54 | $26.79 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $217.66B | $5.01B |
Dividend Yield | 6.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.50, up 0.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings that beat estimates, with net income nearly doubling year-over-year on record production. Recent news highlights a new oil discovery off Amapa and a 22-year LNG supply deal with Cheniere Energy, supporting long-term growth prospects.
PBR presents a compelling value with a low P/E of 6.44 and robust profitability, including a 30.77% ROE. However, the stock trades above the analyst consensus price target of $22.33, and net cash flow turned negative in 2026. Key risks include political interference in Brazil, volatile oil prices, and execution challenges in new projects.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
